Earnings Breakdown: Cytek Biosciences Q4

Benzinga·02/26/2026 21:10:10

Listen to the news

Cytek Biosciences (NASDAQ:CTKB) announced its Q4 earnings on Thursday, February 26, 2026 at 04:05 PM.

Here's a breakdown of the earnings report.

Earnings

Cytek Biosciences missed estimated earnings by -3300.0%, reporting an EPS of $-0.34 versus an estimate of $-0.01.

Revenue was up $4.67 million from the same period last year.

Performance in Previous Earnings

During the previous quarter, the company missed on EPS by $0.03, leading to a 13.22% increase share price change the next day.

Here's a look at Cytek Biosciences's past performance:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.01	-0.04	0.01	0.10
EPS Actual	-0.04	-0.04	-0.09	0.07
Revenue Estimate	51.25M	46.67M	43.30M	59.38M
Revenue Actual	52.29M	45.60M	51.93M	57.48M

To track all earnings releases for Cytek Biosciences visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English